Safety and Efficacy Study of Chemotherapy Plus Apatinib as Second-line Therapy in Metastatic Colorectal Cancer
Status:
Unknown status
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of apatinib in combination
with second-line FOLFOX or FOLFIRI for metastatic colorectal cancer in patients with disease
progression during or after first-line therapy.